Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02295215
Other study ID # NCT01900000
Secondary ID
Status Recruiting
Phase N/A
First received August 25, 2014
Last updated November 14, 2014
Start date June 2013
Est. completion date December 2015

Study information

Verified date June 2013
Source University of Sao Paulo General Hospital
Contact Carlos E Negrão
Phone 5511 26615699
Email cndnegrao@incor.usp.br
Is FDA regulated No
Health authority Brazil: National Committee of Ethics in Research
Study type Interventional

Clinical Trial Summary

The prevalence of Chagas' disease continues high even in the developed countries. Chagasic Cardiomyopathy with preserved ventricular function is an understudied form of Chagas disease. Since a majority of patients with these changes progress to dilated form with ventricular dysfunction with all its serious consequences, it is interesting to better understand the pathophysiology of the disease at the stage where there electrocardiographic changes and preserved ventricular function. And besides, search strategies to slow the progress, or even prevent the chronic phase of the disease. For this reason the investigators will evaluate the effects of exercise training in patients with Chagas cardiomyopathy without ventricular dysfunction.


Description:

Chagasic Cardiomyopathy with preserved ventricular function is an understudied form of Chagas disease. Since a majority of patients with these changes progress to dilated form with ventricular dysfunction with all its serious consequences, it is interesting to better understand the pathophysiology of the disease at the stage where there electrocardiographic changes and preserved ventricular function. And besides, search strategies to slow the progress, or even prevent the chronic phase of the disease. For this reason the investigators will evaluate the effects of exercise training in patients with Chagas cardiomyopathy without ventricular dysfunction.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 25 Years to 60 Years
Eligibility Inclusion Criteria:

- Chagas' disease patients, diagnosed with at least two positive serological reactions to Chagas' disease,

- Ejection fraction =55%

Exclusion Criteria:

- Participation in a regular exercise program in the last 3 months preceding the survey

- Use of oral anticoagulant

- Use of a pacemaker or implantable cardioverter

- Hemodynamic instability

- Myocardial revascularization infarction or unstable angina in the last 3 months of the start of the protocol

- Diabetes mellitus

- Hypertension

- Pulmonary Disease

- Valvular lesions

- Atrial Fibrillation

- Angina of effort

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
Exercise
Exercise Training for 4 months

Locations

Country Name City State
Brazil Heart Institute - HC-FMUSP Sao Paulo SP

Sponsors (1)

Lead Sponsor Collaborator
University of Sao Paulo General Hospital

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sympathetic nerve activityAutonomic control Exercise training will improve baroreflex sensitivity and reduce sympathetic nerve activity. 4 months No
Secondary Peak oxygen consumption Exercise training will improve peak oxygen consumption 4 months No
Secondary Skeletal muscle strength Exercise training will increase skeletal muscle strength 4 months No
See also
  Status Clinical Trial Phase
Completed NCT01162967 - Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole Phase 2
Completed NCT00023556 - Genetic Architecture of Heart Disease in Rural Brazil N/A
Active, not recruiting NCT04024163 - Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease Phase 3
Recruiting NCT05868005 - Delivering a Multi-disease Screening Tool to Migrant Populations N/A
Completed NCT03892213 - Pharmacokinetic Drug-Drug Interaction Study Phase 1
Recruiting NCT00875173 - Selenium Treatment and Chagasic Cardiopathy (STCC) Phase 3
Recruiting NCT03704181 - Colchicine for Patients With Chagas´ Disease( B1 Stage) Phase 2
Active, not recruiting NCT03378661 - BENDITA BEnznidazole New Doses Improved Treatment and Associations Phase 2
Completed NCT01927224 - Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients Phase 1
Completed NCT01006486 - Outcomes of an Anticoagulation Clinic in an University Hospital Phase 4
Completed NCT00123916 - BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease Phase 3
Completed NCT02516293 - Cardiac Rehabilitation in Chagas Heart Failure Phase 2/Phase 3
Completed NCT02517632 - Physical Exercise Program in Chronic Chagas Heart Disease Phase 3
Recruiting NCT02099903 - Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease N/A
Completed NCT01874795 - Effect of Ganglionar Electrical Stimulation on Central Arterial Pressure N/A
Completed NCT01006473 - Exercise Training in Chagas Cardiomyopathy Phase 4
Completed NCT02386358 - Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial Phase 3
Not yet recruiting NCT05477953 - An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
Completed NCT02346123 - Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy N/A
Completed NCT03350295 - Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Phase 1